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ACE inhibitor and angiotensin type I receptor antagonist in
combination reduce renal damage in obese Zucker rats.
Background. In this study, we evaluated whether a combi-
nation of an angiotensin-converting enzyme (ACE) inhibitor,
benazepril (B), with an angiotensin type I receptor antagonist
(AT1RA), irbesartan (I), is as effective or more than drugs as
monotherapy in controlling renal damage in obese Zucker rats
(OZR), a model of metabolic syndrome.
Methods. During six months, G1 (OZR receiving no treat-
ment); G2 (OZR with B 10 mg/kg/day); G3 (OZR with I
50mg/kg/day); and G4 (OZR with B 5mg/kg/day + I 25 mg/
kg/day). Kidneys were processed for light microscopy (LM)
and immunohistochemistry, including antibodies against inter-
stitial a-smooth-muscle-actin (a-SMA), plasminogen activator
inhibitor-1 (PAI-1), transforming growth factor-b 1(TGF-b1),
and collagen (COL) I, III, and IV.
Results. All treated groups presented similar reduction in
blood pressure compared with untreated OZR. However, an-
imals from G4 (B + I) showed better control on proteinuria
together with a higher creatinine clearance. Additionally, G4
showed a significant (P < 0.05) lower kidney weight; smaller
glomerular area; lower glomerulosclerosis score; lower per-
centage of tubular atrophy, interstitial fibrosis, and interstitial
a-SMA; lower tubular PAI-1 score; lower percentage of COL
I, III, and IV in renal interstitium; and lower wall/lumen ratio
in renal vessels, when compared with the other groups. OZR
treated with B and/or I showed a better outcome (P < 0.01)
in the carbohydrate and lipid metabolism in comparison with
untreated OZR.
Conclusion. These results suggest that combined therapy us-
ing B and I is more effective than therapy with either drug at
monotherapy for controlling renal damage in this animal model.
In addition, data presented here reaffirm the benefit of inter-
acting against renin-angiotensin-system (RAS) in the metabolic
syndrome.
The association of obesity, non-insulin dependent dia-
betes mellitus (NIDDM), and arterial hypertension today
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is increasing in prevalence, affecting a large population
worldwide. Furthermore, when together, they constitute
a metabolic syndrome, which is deeply involved in the de-
velopment of cardiovascular and renal disease with dele-
terious consequences. Interestingly, systemic as well as
the local renin-angiotensin-system (RAS) seem to have
an essential role in the pathogenesis of this syndrome
[1, 2]. Adipocytes, which represent the main component
of fat tissue, contain a fully functional local RAS [3, 4].
Therefore, an increase of body fat mass will result in a
local net increase in activity and/or expression of vasoac-
tive systems. In addition, angiotensin II (Ang II) activates
synthesis of adipocyte gene expression, including leptin
and plasminogen activator inhibitor-1 (PAI-1) [5–7]. It
has been reported that Ang II inhibits adipogenic dif-
ferentiation of adipocytes via the angiotensin II type 1
(AT1) receptor, and that the expression of angiotensin-
forming enzymes in adipose tissue is inversely correlated
with insulin sensitivity [8, 9].
In correspondence with these findings, recent clinical
studies suggest that the blockade of RAS, either by in-
hibiting the angiotensin-converting enzyme (ACE), or by
blocking the AT1 receptor, may substantially lower the
risk of type 2 diabetes [10–12]. Therefore, therapeutic in-
tervention in order to control or modulate RAS rises in
importance. Experimental and clinical data have demon-
strated that ACE inhibitors as well as AT1 receptor
antagonists (AT1RA) have been effective in controlling
renal damage in diabetic and nondiabetic nephropathies
[13–19].
Combination therapy is frequently used in an effort
to achieve satisfactory antihypertensive effects at doses
lower than those used in monotherapy, thus diminishing
the incidence of unwanted side effects. Several studies
have confirmed that the increased effectiveness obtained
by a combined treatment with two drugs is obtained be-
cause of the synergy of its components and improved tol-
erance in comparison with the same drugs at higher doses
in monotherapy.
Obese Zucker rats (OZR) are a well-known model of
hypertension, obesity, insulin resistance state, glucose in-
tolerance or mild diabetes mellitus, and hyperlipidemia
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[20–23]. Thus, it is an attractive experimental model to in-
vestigate renal damage related to the human “metabolic
syndrome.” Beyond the fact that both ACE inhibitors and
AT1RAs are widely recognized today as a class of drugs
that can modify the natural evolution of the renal injury
associated with metabolic syndrome, the most important
topic is the potential synergistic effect of these two agents.
Therefore, combined therapy with these drugs acquires
significance. In this regard, the aim of the present study
was to determine whether a combination of an ACE in-
hibitor with an AT1RA is as or more effective than either
drug as monotherapy in this representative model of hu-
man metabolic syndrome.
METHODS
All the experiments were approved by the Hospital
Alema´n Ethic Committee and the Teaching and Re-
search Committee and followed the National Institute
of Health Guide for the Care and Use of Laboratory
Animals. Ten-week-old male Zucker rats, obese (fa/fa)
(OZR), (Charles River Laboratories, Wilmington, MA,
USA) were housed in individual cages at 21 ± 2◦C and a
12-hour light/darkness cycle (7 a.m. to 7 p.m.), and divided
into four groups: OZR group (G1, N = 8); OZR with be-
nazepril (B) group (G2, N = 8); OZR with irbesartan (I)
group (G3, N = 8); and OZR with B and I group (G4,
N = 8). All the animals were allowed to drink tap water,
and fed standard rat chow (16% to 18% protein, Cargill-
Argentine, Buenos Aires, Argentina) ad libitum. In order
to obtain blood pressure control, full doses of B and I were
chosen according to previous studies [19, 24–26]. Half
doses of each drug were employed in combination with
the purpose to achieve equivalent blood pressure lower-
ing. During six months all the animals were treated as the
following schedule: G1 no treatment; G2 received B (10
mg/kd/day); G3 received I (50 mg/kg/day), G4 received B
(5 mg/kg/day) plus I (25 mg/kg/day). B and I were admin-
istered daily between 11:00 a.m. to 12:00 a.m. by gavage.
Dose treatment was adjusted each week based on calcula-
tion of the body weight for each animal. In order to eval-
uate the evolution of proteinuria in each group, 24-hour
urine was collected monthly from baseline to the end of
the experiment (sixth month). Other urinary biochemical
determinations, as well as serum determination, were as-
sessed at baseline and at the end of the experiment. After
six months of treatment all rats were euthanized by subto-
tal exanguination under anesthesia (sodium thiopental
40 mg/kg intraperitoneally) according to institutional
guidelines for animal care and use. The kidneys were
rapidly excised, weighed, and harvested for light mi-
croscopy (LM) and immunohistochemistry studies.
Blood pressure measurement
Systolic blood pressure (SBP) was measured monthly
from baseline to the end of the experiment by tail cuff
plethysmography. Measurements were obtained with the
rats restrained in a plastic chamber without anesthesia.
A pneumatic pulse transducer positioned on the ventral
surface of the tail distal to the occlusion cuff detected
the return of the pulse following a slow deflation of
the cuff. Cuff pressure was determined by a Pneu-
matic Pulse Transducer, using a Programmed electro-
sphygmomanometer PE-300 (Narco Bio-Systems,
Austin, TX, USA), and pulses were recorded on a
Physiograph MK-IIIS (Narco Bio-Systems). A minimum
of three such determinations were taken at each session,
and the SBP registered was the average of the three
readings.
Biochemical procedures
After 14-hour fasting, rat blood samples were collected
from the tail vein in capillary tubes at baseline and at the
end of the experiment from the inferior cava vein before
the rats were sacrificed. Plasma glucose levels were mea-
sured by the glucose oxidase method with an Automatic
Analyzer (Hitachi 911; Tokyo, Japan). Aliquots of sera
and urine were assayed for creatinine using the enzymatic
UV method (Randox Laboratories, Ltd., Crumlin, North-
ern Ireland). Serum cholesterol and triglycerides were
assessed according to standard methods. Serum insulin
was determined by a solid phase two-site immunoassay
with monoclonal antibodies (DRG Instruments GmbH,
Marburg, Germany). Serum samples were stored before
testing. The detection limit of the test was 0.07 lg/L, calcu-
lated as two standard deviations above the zero standard.
Total CV% of the assay was 4%. Proteinuria as well as
serum and urine electrolytes were determined by stan-
dard methods.
Kidney processing and examination
Kidneys were perfused with saline solution through the
abdominal aorta until it was free of blood. Decapsulated
kidneys were cut longitudinally and fixed in phosphate-
buffered 10% formaldehyde (pH 7.2), and embedded in
paraffin. Three-micron sections were cut and stained with
hematoxylin-eosin (H&E), periodic acid-Schiff reagent
(PAS), and Masson’s trichrome. All observations in LM
were performed using a Nikon E400 light microscope
(Nikon Instrument Group, Melville, NY, USA).
Immunohistochemical staining
Paraffin sections were cut at 3 lm, deparaffined, and
dehydrated. Endogenous peroxidase activity was blocked
by treating with 0.5% H2O2 in methanol for 30 min-
utes. Monoclonal antibodies against transforming growth
factor-b 1(TGFb 1; Santa Cruz Biotechnology, Inc., Santa
Cruz, CA, USA) at a dilution 1:100 and anti-collagen
type I (COL I); type III (COL III), and type IV (COL
IV) (Biogenex, San Roman, CA, USA) at a dilution
1:100 were used to evaluate the process of fibrosis. Renal
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Table 1. Baseline parameters
G1 (N = 8) G2 (N = 8) G3 (N = 8) G4 (N = 8)
Mean ± SD OZR OZR with B OZR with I OZR with B + I P value
Rat body weight g 303.7 ± 14.5 305.7 ± 9.8 302.2 ± 13.9 306.2 ± 9.2 NS
Glycemia mmol/L 6.4 ± 0.5 6.2 ± 0.3 6.5 ± 0.5 6.4 ± 0.3 NS
Insulin pmol/L 175.7 ± 28.3 184.4 ± 30.9 180.2 ± 28.9 182.1 ± 32.7 NS
Insulin/glucose ratio 27.1 ± 2.8 29.2 ± 3.9 27.9 ± 5.1 28.0 ± 4.6 NS
Triglycerides mmol/L 0.82 ± 0.16 0.81 ± 0.18 0.83 ± 0.16 0.82 ± 0.18 NS
Cholesterol mmol/L 1.33 ± 0.18 1.34 ± 0.18 1.32 ± 0.19 1.35 ± 0.16 NS
Creatinine clearance mL/min 3.08 ± 0.14 2.99 ± 0.13 3.10 ± 0.16 3.02 ± 0.16 NS
[Na+]s mmol/L 145.3 ± 2.5 145.5 ± 2.3 144.7 ± 2.1 145.5 ± 2.6 NS
[K+]s mmol/L 4.8 ± 0.2 4.8 ± 0.1 4.8 ± 0.1 4.7 ± 0.2 NS
Abbreviations are: B, benazepril; I, irbesartan; NS, not significant.
a-smooth-muscle actin (a-SMA) was quantified using
anti-mouse a−SMA, (Sigma Chemical Co., St. Louis,
MO, USA) monoclonal antibody. In order to evaluate
PAI-1 in renal tissue, a polyclonal rabbit anti-rat IgG anti-
PAI-1 (American Diagnostica, Greenwich, CT, USA) at
a dilution 1:100 was used. Immunostaining was carried
out with a commercial modified avidin-biotin-peroxidase
complex technique (Vectastain ABC kit; Universal Elite,
Vector Laboratories, CA, USA), counterstained with
hematoxylin, and the samples handled as previously de-
scribed. [27].
Morphologic analysis
All tissue samples were evaluated independently by
two investigators without previous knowledge of the
group to which the rat belonged. A semiquantitative
score, as previously described by Raij et al [28], was per-
formed to estimate glomerulosclerosis. A minimum of 20
glomeruli (range 20 to 40) in each specimen was exam-
ined and the severity of the lesion was graded from 0 to
4+ according to the percentage of glomerular involve-
ment. Thus, a 1+ lesion represented an involvement of
25% of the glomerulus while a 4+ lesion indicated that
100% of the glomerulus was involved. An injury score
was then obtained by multiplying the degree of injury,
which corresponds to glomerulosclerosis. Interstitial fi-
brosis, tubular atrophy, interstitial a-SMA, TGFb 1, COL
I, COL III, and COL IV in interstitium, were assessed on
20 consecutive microscopic fields at 400× magnification,
where each field represents 1.13 mm2, resulting in a total
explored area of 22.6 mm2. Data were averaged, and the
result was expressed as a percentage. PAI-1 was assessed
using semiquantitative scores as previous described [29],
where glomerular PAI-1 was scored as: 0 = no staining;
1+ = <10% of each glomerular tuft; 2+ = 10% to 25%;
and 3+ = ≥25% of each tuft. Vascular PAI-1 was scored
as: 0 = no staining; 1+ = occasional positive vessels; 2+ =
<50%; and 3+ = ≥50% of vessels staining. Tubular PAI-
1 was scored as: 0 = no staining; 1+ = weak, very focal
<10% of tubules; 2+ = mild-moderate in 10% to 30%
of tubules; and 3+ = moderate-severe in ≥30% tubules.
All measurements were carried out using an image an-
alyzer Image-Pro Plus, version 4.5, for Windows (Media
Cybernetics, LP, Silver Spring, MD, USA).
Statistical method
Values were expressed as mean ± SD. All the statis-
tical analyses were performed using absolute values and
processed through GraphPad Prism, version 2.0 (Graph-
Pad Software, Inc., San Diego, CA, USA). The assump-
tion test to determine the Gaussian distribution was
performed by the Kolmogorov and Smirnov method. For
parameters with Gaussian distribution, all the compar-
isons among groups were carried out using analysis of
variance (ANOVA). The difference of mean values be-
tween groups was assessed by Tukey-Kramer multiple
comparisons test. Statistical analysis for those parameters
such as histologic data with non-Gaussian distribution
was performed by Kruskal-Wallis test (nonparametric
ANOVA) and Dunn’s multiple comparison test. A value
of P < 0.05 was considered to be significant.
RESULTS
At baseline, all the animals presented no significant
differences with respect to the variables evaluated, as il-
lustrated in Table 1. All the rats were significantly heavier
throughout the experiment, from the beginning to the end
of the study, as observed in Tables 1 and 2. OZRs, which
had received no treatment throughout the study, exhib-
ited an increase in blood pressure, as monthly evolution
shows in Figure 1A. At the same time, as expected, OZR
that had received treatment with B, I, or both, displayed
a significant lower level in their blood pressure which, in
fact, was quite similar between them, as demonstrated
in Figure 1A. Additionally, there were no significant
differences in blood pressure between the groups that
had received treatment at all the time points examined
(Fig. 1A). In relation with proteinuria and glomerular
function, while animals from G1 (OZR) developed overt
and progressive proteinuria along with a decline in the
creatinine clearance during the experiment, those rats
that had received a single treatment with either B or I
presented a significant (P < 0.01) reduction in proteinuria
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Table 2. Parameters at the end of the experiment
G1 (N = 8) G2 (N = 8) G3 (N = 8) G4 (N = 8)
Mean ± SD OZR OZR with B OZR with I OZR with B+I P value
Rat body weight g 616.6 ± 39.9 598.6 ± 44.9 593.2 ± 47.1 607.6 ± 45.5 NS
Glycemia mmol/L 12.7 ± 0.5 12.3 ± 0.4 12.2 ± 0.4 12.0 ± 0.5 NS
Insulin pmol/L 750.5 ± 112.5a 494.6 ± 63.0b 480.0 ± 83.3c 472.6 ± 72.6
Insulin/glucose ratio 59.0 ± 8.7a 40.0 ± 4.1b 39.1 ± 7.6c 39.2 ± 5.4
Triglycerides mmol/L 11.3 ± 1.8a 7.8 ± 2.0b 7.5 ± 1.9c 7.1 ± 2.0
Cholesterol mmol/L 5.3 ± 0.3a 3.8 ± 0.5b 3.7 ± 0.5c 3.4 ± 0.4
Creatinine clearance mL/min 2.38 ± 0.22a 3.06 ± 0.11b 3.15 ± 0.12 3.56 ± 0.17d
Creatinine clearance/100 g body weight 0.38 ± 0.05a 0.51 ± 0.03b 0.53 ± 0.04 0.59 ± 0.05d
[Na+]s mmol/L 144.1 ± 2.4 143.2 ± 3.0 143.1 ± 2.3 143.6 ± 2.3 NS
[K+]s mmol/L 4.9 ± 0.4 5.3 ± 0.2 5.1 ± 0.2 5.1 ± 0.3 NS
Abbreviations are: B, benazepril; I, irbesartan; NS, not significant.
avs. all groups P < 0.01.
bvs. G3 and G4; P = not significant.
cvs. G4; P = not significant.
dvs. G2 and G3 P < 0.05.
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Fig. 1. Monthly evolution of systolic blood
pressure in each group (A). ∗ OZR (G1) vs.
all groups P < 0.01 at sixth months. Evolution
of proteinuria in each group throughout the
study (B). ∗ OZR (G1) versus all groups P <
0.01. ∗∗ OZR + B + I vs. all groups P < 0.01
at sixth months. OZR, obese Zucker rats.
together with a higher creatinine clearance. However,
the best outcome obtained on these two parameters was
achieved in the combine therapy group (G4), as observed
in Table 2 and Figure 1B. With respect to carbohydrate
metabolism, all groups presented normal glycemia with
overt hyperinsulinemia at baseline (Table 1). In contrast,
at the end of the experiment, while all groups displayed
similar degrees of hyperglycemia, those animals from G1
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Table 3. Morphologic and immunohistochemical parameters at the end of the experiment
G1 (N = 8) G2 (N = 8) G3 (N = 8) G4 (N = 8)
Mean ± SD OZR OZR with B OZR with I OZR with B + I
Total kidney weight g 3.53 ± 0.15b 2.83 ± 0.15c 2.74 ± 0.19 2.48 ± 0.10d
Total kidney weight % of body weight 0.57 ± 0.03b 0.47 ± 0.04c 0.46 ± 0.04 0.41 ± 0.03d
Glomerular area l2 4692 ± 0.256b 3214 ± 0.185c 3,305 ± 0,180 2904 ± 0.120d
Glomerulosclerosis score 2.16 ± 0.34b 0.65 ± 0.26c 0.61 ± 0.26 0.17 ± 0.25d
Tubular atrophya % 9.8 ± 1.1b 4.0 ± 0.8c 4.0 ± 1.1 1.8 ± 0.4d
Interstitial fibrosisa % 4.7 ± 0.6b 1.6 ± 0.4c 1.1 ± 0.3 0.5 ± 0.2d
Interstitial a-SMAa % 10.9 ± 1.1b 1.7 ± 0.7c 1.5 ± 0.4 0.5 ± 0.5d
Tubulointerstitial TGFb 1a % 36.8 ± 3.7b 10.2 ± 2.7c 8.1 ± 2.1 3.6 ± 1.6d
Glomerular PAI-1 score 1.25 ± 0.46b 0.25 ± 0.46 0.0 ± 0.0 0.0 ± 0.0
Vascular PAI-1 score 2.87 ± 0.35b 0.75 ± 0.88 0.12 ± 0.35 0.12 ± 0.35
Tubular PAI-1 score 2.87 ± 0.35b 2.12 ± 0.64 1.50 ± 0.53 0.12 ± 0.35d
COL Ia % 4.7 ± 0.5b 1.2 ± 0.2c 1.0 ± 0.3 0.3 ± 0.3d
COL IIIa % 10.1 ± 1.2b 3.8 ± 0.4c 3.2 ± 0.6 1.7 ± 0.7d
COL IVa % 8.3 ± 0.6b 2.3 ± 0.3c 1.8 ± 0.2 1.1 ± 0.3d
Wall/lumen ratio in renal vessels 1.3 ± 0.1b 1.0 ± 0.1c 1.0 ± 0.1 0.7 ± 0.1d
Abbreviations are: B, benazepril; I, irbesartan; a-SMA, a-smooth muscle actin; TGFb 1, transforming growth factor b 1; PAI-1, plasminogen activator inhibitor-1;
COL I, collagen type I; COL III, collagen type III; COL IV, collagen type IV.
aPercentage/22.6 mm2.
bvs. all groups P < 0.01.
cvs. G3; P = not significant.
dvs. G2 and G3; P < 0.05.
(OZR) presented a significant higher level of insuline-
mia with respect to the other groups, which showed no
differences between them (Table 2). Consequently, in-
sulin/glucose ratio was significantly lower (P < 0.01) in
these groups that received therapy with B and/or I, as
indicated in Table 2, thus suggesting some improvement
in the insulin resistance state. At the end of the experi-
ment, both cholesterol and triglycerides were higher (P <
0.01) in the untreated animals (G1, OZR) with respect to
the other groups, which presented similar values without
differences between them (Table 2). There were no sub-
stantial modifications in the groups with respect to serum
electrolytes throughout the study (Tables 1 and 2).
Morphologic and immunohistochemical findings
At the end of the experiment, untreated rats (G1)
showed a total kidney weight significantly higher (P <
0.01) than the other groups who also presented some dif-
ferences between them (Table 3). It is worth mentioning
that the combined therapy group (G4) showed the lowest
value (P < 0.05) in total kidney weight. Glomerular area
was markedly increased in untreated animals (G1) with
respect to those that received either B and/or I. Although
rats from G2 (B) and G3 (I) showed a significant control
in the glomerular size, those animals with combined treat-
ment (G4) exhibited the most relevant outcome on this
particular point (Table 3). Remarkable glomerulosclero-
sis, tubular atrophy, and interstitial fibrosis characterized
by an increase in the percentage of COL I, COL III,
and COL IV were found in rats from G1 (Table 3 and
Fig. 2). Moreover, interstitial a-SMA, as well as the pos-
itive tubulointerstitial area for TGFb1 was significantly
(P < 0.01) increased in the same group (Table 3 and Figs. 3
and 4). On the contrary, while animals which had received
B (G2) or I (G3) as monotherapy presented a substan-
tial (P < 0.01) reduction in all these lesions (Table 3 and
Figs. 2 to 4), those with both drugs in combination (G4)
obtained a significant (P < 0.05) further protection, as
shown in Table 3 and Figures 2 to 4.
Glomerular, vascular, and tubular PAI-1 scores showed
that rats that had not received treatment presented higher
scores in comparison with the other groups (Table 3 and
Fig. 5). In contrast, animals from those groups receiv-
ing B and/or I showed lower values, with similar re-
sults regarding glomerular and vascular PAI-1 expression
(Table 3 and Fig. 5). However, animals with combined
therapy presented the lowest (P < 0.05) tubular PAI-1
score (Table 3).
Finally, concerning renal vessels involvement, while
untreated OZR presented the highest wall/lumen ratio,
those rats with B (G2) or I (G3) displayed a consider-
able reduction in this ratio, but again, the lower ratio was
exhibited by the G4 (B + I) animals (Table 3).
DISCUSSION
Undoubtedly, in the present study, untreated OZR
presented a significant increase in blood pressure along
with remarkable renal damage characterized by either
glomerular and tubulointerstial lesions, which were ex-
pressed through significant proteinuria together with a
decrease in the glomerular function, as represented by
a lower creatinine clearance. In contrast, OZR which
had received treatment with either B or I showed a clear
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A
B
Fig. 2. Important degree of glomerulosclerosis, tubular atrophy, dilatation, and protein cast in tubular lumen, along with interstitial fibrosis in
untreated OZR (A). Photomicrograph illustrate renal sections from OZR treated with benazepril (B), irbesartan (C), and both drugs in combination
(D), respectively. Note appreciable benefit with each treatment, but especially with the combine therapy (D). (Masson’s trichrome, magnification
×100). OZR, obese Zucker rats.
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Fig. 2. Continued.
benefit on all the above-mentioned aspects. Interestingly,
beyond showing no difference in blood pressure control
in comparison with the other treated group, OZR with
the combined therapy at a lower dose of each drug pre-
sented a better outcome in mostly evaluated parameters
in this study. The favorable renal effects of combined ther-
apy using an ACE inhibitor and AT1RA on this animal
model of metabolic syndrome could be explained by the
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A
B
Fig. 3. Representative photomicrograph from renal cortex showing a-smooth muscle actin (a-SMA) immunostaining in all groups. Intense per-
itubular staining in untreated OZR (A). Appreciable reduction in the interstitial amount of a-SMA in animals treated with benazepril (B), irbesartan
(C), and mostly with combined therapy (D). Note in this last group that the vascular wall only presents positive immunostaining (anti–a-SMA,
magnification ×400). OZR, obese Zucker rats.
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D
Fig. 3. Continued.
2352 Toblli et al: Combination of ACEi with AT1RA protects renal tissue in Zucker rats
A
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Fig. 4. Renal cortex sections with immunostaining for transforming growth factor b1 (TGFb1) in all groups. (A) shows large area with positive
staining in untreated OZR. Considerable decrease in TGFb 1 is observed in animals with benazepril (B) and irbesartan (C), but paramount reduction
was appreciated in the combined therapy group (D) (anti-TGFb 1, magnification ×400). OZR, obese Zucker rats.
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Fig. 4. Continued.
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A
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Fig. 5. Representative images from renal cortex showing localization corresponding to plasminogen activator inhibitor-1 (PAI-1) immunostaining
in all groups. Note extensive positive staining in untreated OZR (A), especially in tubular epithelial cells. Lower amount of PAI-1 is observed in
treated group as shown in benazepril (B), but especially in irbesartan (C), and almost undetectable in the combined therapy group (D) (anti–PAI-1,
magnification ×400). OZR, obese Zucker rats.
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Fig. 5. Continued.
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synergic action of these two different classes of drugs on
local and systemic RAS.
OZR possess low plasma renin values, and some data
indicate that they display a significantly reduced contrac-
tile response to Ang II at 10 and 24 weeks of age when
compared with lean age-matched controls [30]. There-
fore, it is probable that nonhemodynamic effects of dual
blockade of RAS take a relevant role, which could justify
the protective outcome observed in the present study.
Both I and B produce dose-related reduction in blood
pressure [19, 24–26]. However, the decrease in blood
pressure does not seem to be enough to explain total
renal damage control in our experiment because an
equivalent hypotensive effect was achieved with each
monotherapy. Furthermore, lowering blood pressure is
probably not sufficient for ameliorating renal damage in
OZR, as demonstrated by Crary et al [31], where the au-
thors, using losartan, an AT1RA, reduced blood pressure
without effect on renal structural lesions. Conversely, in
the study of O’Donnel et al, using OZR, the authors em-
ployed I when rats were 26 weeks old, by 18 weeks at
low (15 mg/kg/day), and high (50 mg/kg/day) doses, and
they found that even at low doses, I was associated with a
moderate reduction in renal lesions, despite the fact that
it did not control proteinuria [19].
Both B, throughout its active metabolite benazeprilat,
and especially I, by their greater lipid solubility can pen-
etrate into deep compartments; therefore, they achieve
substantial renal concentration and a higher RAS con-
trol [32–35]. Because Ang II actions may include direct
effects of intracellular Ang II to regulate nuclear signal-
ing events, which contribute to the progression of renal
diseases [36], both reduction in Ang II production and/or
its disposability for binding with the AT1 receptor are
essential for providing a better nephroprotection. Even
though in the present experiment we did not measure
ACE activity, we assume that adequate ACE inhibition
is achieved in the combined therapy group because B at
4 mg/kg/day has demonstrated to control ACE activity,
as reported by Li et al [37]. Consequently, in our study,
synergistic action of I with B, which possesses a potent
and long-acting ACE inhibition even at low dose [37],
may explain the favorable outcome on renal lesions in
the combine therapy group.
Dual blockade of RAS can provide a synergistic action
to achieve greater suppression in the Ang II effects by
inhibiting ACE (in plasma and in tissue), and by block-
ing the AT1 receptor. In addition, because a proportion
of Ang II in tissue is produced by non-ACE dependent
pathway (chymase), the presence of AT1 blockade pro-
vides a substantial help to control local RAS activity
beyond ACE inhibition. Additionally, unlike ACE inhi-
bition, AT1 blockade increases circulating Ang II levels,
leading to the stimulation of AT2 receptor, which has
anti-growth, anti-proliferation, and proapoptotic actions
[38]. Furthermore, it has been demonstrated that AT1
receptor blockade increases renal bradykinin, which also
has anti-growth actions, and cGMP level via the AT2 re-
ceptor, an effect which was further potentiated by ACE
inhibition by B [39].
A cross-talk between Ang II and metabolic insulin
pathway has been reported [40]. Throughout the AT1
receptor Ang II blocks the metabolic action of insulin,
but not the proliferative ones [41]. Moreover, insulin can
potentiate proliferative actions of Ang II by inducing
up-regulation of the AT1 receptor [42]. Ang II inhibits
the insulin-induced activation of phosphoinsital-3-kinase
(PI-3K), which is involved in the glucose-transporter-4
(GLUT-4) protein translocation to the plasmatic mem-
brane, such protein facilitating the glucose transport
into the cell. Abnormalities of GLUT-4 protein have
been well documented in OZR [43–45]. In the present
study, OZR receiving B, I, or combined therapy showed
lower insulin/glucose ratio in comparison with untreated
OZR. Previous investigations have demonstrated that
administration of ACE inhibitors, as well as AT1RA, are
associated with enhancement of whole-body insulin sen-
sitivity in a variety of insulin-resistant animal models, or
in insulin-resistant humans with essential hypertension
[46–51]. Both ACE inhibitors and AT1RA can increase
protein expression of GLUT-4 in skeletal muscle and my-
ocardium, possibly by the nitric oxide dependent effect
of bradykinin and/or antagonism of Ang II by blocking
AT1 receptor [52, 53]. Therefore, and as it has been shown
in our study, dual blockade even at a low dose can im-
prove the insulin-resistant state. Because insulin resis-
tance plays a central role in the metabolic syndrome, we
can speculate that mostly favorable effects observed in
the present experiment are likely to be seen in other ani-
mal models such as dietary-induced model of obesity and
hypertension or fructose-fed hypertensive rats.
Because both proteinuria and arterial hypertension
are recognized as major risk factors for developing
renal insufficiency, efforts to achieve tight proteinuric
as well as blood pressure control acquire importance.
Numerous experiments and clinical trials have largely
demonstrated the beneficial effect of the RAS blockade
for preserving renal structures and function in the major-
ity of nephropathies. However, despite the fact that phar-
macologic agents that interact against RAS have largely
proved that they reduce proteinuria at monotherapy,
there are some relevant points for using combined ther-
apy of these drugs. For instance, when obesity, diabetes,
hyperlipidemia, and arterial hypertension are present to-
gether, there is less possibility to achieve the goal out-
come in renal function, proteinuria, and blood pres-
sure control with monotherapy [54]. Recently, clinical
studies in diabetic and nondiabetic nephropathies have
demonstrated that at comparable blood pressure, com-
bined ACE inhibitors and AT1RA decreased proteinuria
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better than ACE inhibitor or AT1RA alone [55–57].
In the present study, the OZR with combined therapy
showed a better proteinuria control compared with the
other groups, which indicates how useful the double in-
teraction with RAS is in this multiple risk factor animal
model.
Both glucose and blood pressure control are very im-
portant to obtain a better prognosis in patients with type
II diabetes mellitus. Nevertheless, cardiovascular or renal
complications have a better outcome when tight blood
pressure control is achieved in comparison with tight glu-
cose control [58]. Notably, data presented in our study
are quite congruent with this clinical observation because
OZR treated with either B and or I, despite having sim-
ilar glycemia to untreated OZR but with a tight blood
pressure control, showed a clear renal protection. Pro-
longed high glucose concentration environment is associ-
ated with an increase in the expression of both PAI-1 and
TGFb 1 [59–61]. Moreover, glucose tolerance and insulin
resistance states are also closely related with PAI-1 con-
centration in subjects with overweight or obesity [62]. In
addition, experimental data provide evidence supporting
that the degree of hyperinsulinemia contributes directly
to elevate PAI-1 in obesity and non–insulin-dependent di-
abetes mellitus [63]. In agreement with this information,
in the present study, untreated OZRs showed a remark-
able high renal expression of both PAI-1 and TGFb 1.
Because these two factors are essential in the develop-
ment of the fibrotic process, therefore, it is not surprising
that untreated OZRs in the present experiment exhib-
ited considerable collagen accumulation in renal tissue.
Nevertheless, despite having a similar degree of blood
glucose, OZR that had received B or I, but especially
those with combined therapy, presented a significantly
lower value in these variables, which suggests an impor-
tant control on both PAI-1 and TGFb 1 expressions by
interacting RAS in a high insulin and glucose environ-
ment. RAS as well as insulin resistance state have both
been identified as major regulators of PAI-1 in hyperten-
sive patients [64]. In the rat, independent of its effects
on blood pressure, Ang II induces PAI-1 directly through
the AT1 receptor in a variety of tissues, including kid-
ney [65]. Furthermore, by increasing PAI-1 expression,
Ang II stimulates fibrinolytic and TGFb 1 activity [66]. On
the other hand, both ACE inhibition and AT1 receptor
antagonism have demonstrated decrease of PAI-1 [67].
Additionally, in obese diabetic mice (C57BL/6Job/ob),
which are normotensive, fibrosis was blunted by ACE in-
hibition, indicating that this effect is independent of the
blood pressure–lowering outcome [68].
Leptin, an adipocyte-secreted hormone that regulates
appetite and energy expenditure, has shown to have profi-
brotic effects by presenting a synergic action with Ang
II through stimulating TGFb 1 [69]. Convincing evidence
indicates that both leptin and TGFb 1 together exert an
additive effect on collagen production [70]. In our study,
interaction against RAS by either B or I, but especially
the association of these two drugs, seems to produce an
actual benefit by decreasing TGFb 1 and, therefore, re-
ducing tubulointersticial fibrosis and glomerulosclerosis
in these animals. However, because OZR is a model char-
acterized by recognized hyperleptinemia, but also by lack
of functional leptin receptor, data in the present study
suggest that the protective effect of combined therapy
with ACE inhibitors/AT1RA is not dependent on the
presence of functional leptinergic system.
CONCLUSION
We think that the data shown in the present study pro-
vide valuable information to address the usefulness of
a combined therapy with ACE inhibitors together with
AT1RA to achieve a tight control in proteinuria and
blood pressure, along with preservation of renal function
in a multiple risk factor scenario. Finally, combined ther-
apy seems to improve the deleterious effect of metabolic
syndrome and, therefore, although we need clinical stud-
ies in order to confirm these results in human beings,
it could be taken into account in future therapeutic ap-
proaches in patients with obesity, hypertension, and dia-
betes or glucose intolerance.
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